Skip to main content
. Author manuscript; available in PMC: 2012 Mar 1.
Published in final edited form as: Gastroenterology. 2010 Nov 25;140(3):879–891.e18. doi: 10.1053/j.gastro.2010.11.037

Figure 2.

Figure 2

Gastrin suppresses MNU-dependent gastric carcinogenesis. (A) Macroscopic photographs of the whole stomach (left) and antrum (right) in MNU-treated WT and INS-GAS mice at 36 weeks. Dotted lines define the border between the corpus and the antrum. Higher magnifications of boxed sections indicate the antrum. Arrows indicate macroscopic tumors. Bars, 2mm. (B) Incidence (percentage of tumor-bering mice/total examined mice in each group), tumor number, tumor size of gastric tumors in MNU-treated WT and INS-GAS mice. **P<0.01. (C) Histopathologic features of gastric tumors in MNU-treated WT and INS-GAS mice at 36 weeks. MNU-treated WT mice (a-f). a. Hyperplastic polyp b. Adenoma c. intramucosal adenocarcinoma d. Invasive adenocarcinoma e. and f. higher magnifications of boxed sections in (c) and (d). mm, muscularis mucosa. MNU-treated INS-GAS mice (g, h). g. Hyperplastic polyp h. Adenoma Bars, 100 µm (D) Histologic grade of the most advanced tumor in tumor-bearing MNU-treated WT and INS-GAS mice. *P<0.05.